(Q34294994)

1 August 2017

0 references

Is alpha/beta for prostate tumors really low? (English)

1 reference

1 August 2017

Fowler J

1

1 reference

1 August 2017

Chappell R

series ordinal

2

1 reference

1 August 2017

Ritter M

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

International Journal of Radiation Oncology Biology Physics

1 August 2017

1 reference

1 August 2017

50

1 reference

1 August 2017

1021-1031

1 reference

1 August 2017

4

1 reference

Fractionation and protraction for radiotherapy of prostate carcinoma

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

What is the T(pot) for prostate cancer? Radiobiological implications of the equivalent outcome with (125)I or (103)Pd.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Toward optimal external-beam fractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Dose, volume, and tumor-control predictions in radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Direct analysis of quantal radiation response data

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Dose selection for prostate cancer patients based on dose comparison and dose response studies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

External beam radiotherapy dose response of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Isotope selection for patients undergoing prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Analysis of Categorical Data by Linear Models

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Guidance to users of Nycomed Amersham and North American Scientific, Inc., I-125 interstitial sources: dosimetry and calibration changes: recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcom

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Regarding Vicini et al., IJROBP 1999,45:553-561

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

Hypofractionation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901607-8

7 January 2021

10.1016/S0360-3016(01)01607-8

Identifiers

DOI

1 reference

1 August 2017

1 reference